

## Product Update:

aprepitant (Emend®) 80mg, 125mg hard capsules  
aprepitant (Emend®) 125mg powder for oral suspension

SMC No. (1252/17)

Merck Sharp & Dohme Limited

09 June 2017

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

aprepitant (Emend®) is accepted for use within NHS Scotland.

**Indication under review:** As part of combination therapy, for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to <12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).

SMC has previously accepted aprepitant for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy in adults. The marketing authorisation has since been extended to cover prevention of nausea and vomiting in adults associated with highly emetogenic non-cisplatin based chemotherapy. SMC does not plan to assess this minor licence extension.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 09 May 2017.*

**Chairman**  
**Scottish Medicines Consortium**

Published 10 July 2017